On August 3, METIS TECHBIO-P (07666) announced that its self-developed AiTEM AI drug formulation innovation platform will be locally deployed at HENGRUI PHARMA (600276.SH, 01276) to enhance drug formulation development efficiency.

This partnership marks the continued external commercialization of the AiTEM platform, driven by the NanoForge technology, and signals the evolution of NanoForge as an AI4S research infrastructure.

NanoForge is a proprietary AI nano-delivery platform developed by METIS TECHBIO-P, integrating AI lipid generation algorithms, lipid foundational models, intelligent agents, and a high-throughput experimental closed-loop system.

According to the company's prospectus, the platform has accumulated over 10 million lipid structures and 100,000 experimental data points, supporting more than 10 innovative drug research pipelines, with breakthroughs in targeted delivery to key human organs and tissues.

The AiTEM platform, powered by the NanoForge technology engine, leverages quantum chemistry and molecular dynamics simulations to optimize drug formulation design, improving drug solubility, bioavailability, and pharmacokinetic profiles.

In the AI-powered MTS-004 formulation new drug project, AiTEM shortened the preclinical formulation optimization cycle from the industry standard of one to two years to less than three months, completing the project from initiation to Phase III clinical trials in just 38 months, significantly boosting R&D efficiency.

Analysts believe that the local deployment of AiTEM at HENGRUI PHARMA signifies a shift from single-project collaboration to platform-based output in AI-driven drug development.

For METIS TECHBIO-P, partnering with a leading domestic innovative drug company not only validates the industrial value of its AI platform but also helps establish a replicable business model, enabling broader deployment of AI research platforms to more pharmaceutical companies and accelerating the commercialization of AI drug development infrastructure.